FDA Approves Zuranolone for Postpartum Depression

The approval marks the first indication for a postpartum depression drug—one that which has been touted for its rapid-acting effect and sustained benefits.

Related Keywords

United States ,American ,Sagarv Parikh ,Andrewj Cutler ,Anita Clayton ,Wilfordw Spradlin ,Kuntzl Zuranolone ,Johnf Greden ,Kunzmannk Zuranolone ,Beth Israel Lahey Health ,University Of Virginia School Medicine ,Drug Administration ,Postpartum Depression In Clinical Program ,Hcplive Peer Exchange ,Biogen Inc ,American Psychiatric Association ,Sage Therapeutics ,Hamilton Depression Rating Scale ,New Orleans ,Virginia School ,Peer Exchange ,Clinical Neuroscience ,Mount Auburn Hospital ,First Oral Treatment ,New Data Presented ,American College ,Published December ,Biogen Announce ,Postpartum Depression Met ,All Key Secondary ,Benefits Major Depression ,Postpartum Depression ,Published May ,Zuranolone Use ,Published January ,Zuranolone ,Major Depressive Disorder ,Mmdd ,Depression ,Ppd ,Fda ,Sage ,Biogen ,